Neovii Biotech
Closed portfolio snapshot
According to ClinicalTrials.gov-derived indexes, Neovii Biotech sits in the upper quartile of US sponsors by registered trial count (#2,411 of 15,742 sponsors by registered trial count).
Neovii Biotech: 5 sponsored US clinical trials, none currently recruiting.
Neovii Biotech sponsors 5 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 4 completed. 2 of these trials are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Adult Acute Lymphoid Leukemia, with 1 trials.
Upper-quartile sponsor footprint
Neovii Biotech sits in the upper quartile of the sponsor corpus (#2,411 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Indexed trials (enrollment closed)
5 total, page 1 of 1
Study of US-ATG-F to Prevent Chronic Graft Versus Host Disease (GVHD)
NCT01295710
Phase II Study With the Trifunctional Antibody Ertumaxomab to Treat Metastatic Breast Cancer After Progression on Trastuzumab Therapy
NCT00522457
Safety and Efficacy Study of Catumaxomab to Treat Ovarian Cancer After a Complete Response to Chemotherapy
NCT00377429
Study of the Trifunctional Antibody Catumaxomab to Treat Recurrent Symptomatic Malignant Ascites
NCT00326885
EZ-2053 in the Prophylaxis of Acute Pulmonary Allograft Rejection
NCT00105183
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 3 |
| Phase 3 | 2 |
Therapeutic Areas
How the Neovii Biotech archive is shaped
5 indexed studies, none listed as recruiting (0% open); 4 completed (80%).
Phase mix: 2 late (III/IV) vs 3 early (I/II) (balanced across stages).
Top condition: Adult Acute Lymphoid Leukemia (1 trial), 4 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
Neovii Biotech: archived-pipeline peers nationwide
Peers matched on 5 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
Neovii Biotech sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 5 archived trials
- 4YouandMe · 5 trials · 0% recruiting
- Abbott Rapid Dx · 5 trials · 0% recruiting
- Access Business Group · 5 trials · 0% recruiting
- Acera Surgical · 5 trials · 20% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
Related
What to do with this Neovii Biotech page
5 registered trials is a research-attention snapshot, not an endorsement of Neovii Biotech or any single study.
- None of Neovii Biotech's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Adult Acute Lymphoid Leukemia is the condition Neovii Biotech studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Adult Acute Lymphoid Leukemia trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Neovii Biotech pipeline card: 5 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.